PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
PTC reported Q1 2026 total revenue of $272.6 million, with product revenue jumping 47% year-over-year to $225.6 million, driven by the global launch of Sephience. The company raised full-year 2026 product revenue guidance to $750-$850 million, citing strong momentum where Sephience revenue grew 36% quarter-over-quarter to $125 million. Pipeline progress included positive topline results from the PIVOT-HD extension study for votoplam and a $50 million milestone payment from partner Novartis following the first patient dosed in the Phase 3 INVEST-HD study.
Key figures
- Revenue
- 272551000
- Guidance
- Total product revenue guidance raised to $750 to $850 million, with expected total revenue of $1.08 to $1.18 billion
- Cash balance
- 1892463000
- Product revenue
- 225600000
- Sephience revenue
- 124600000
- Sephience qoq growth
- 36%
- Milestone payment usd
- 50000000
- Product revenue growth
- 47%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.